Risk factors for Abacavir-induced hypersensibility syndrome in the "real world";Facteurs de risque de syndrome d'hypersensibilité à l'Abacavir en pratique clinique de routine

Pathologie Biologie

Volumn 52, Issue 9 SPEC.ISS., 2004, Pages 529-533

  Chirouze, C ^a   Hustache Mathieu, L ^a   Rougeot, C ^a   Drobacheff, C ^a   Gil, H ^a   Faller, J P ^a   Lebrun, C ^a   Estavoyer, J M ^a   Henon T ^a   Hoen, B ^a  

^a HÔPITAL SAINT JACQUES   (France)

Author keywords

Abacavir; Abacavir induced hypersensibility syndrome; Facteurs de risque; HIV patients; Infection par le VIH; Syndrome d'hypersensibilit

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; NEVIRAPINE;

ADULT; CAUSE OF DEATH; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL RECORD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYALGIA; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RISK; RISK FACTOR;

EID: 8644245792     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.07.012     Document Type: Article

References (21)

1. Hewitt R.G. Abacavir hypersensitivity reaction Clin Infect Dis 34 2002 1137 1142
2. Cutrell A., Edwards M., Steel H., Symonds W., Spreen B., and Powell G. Risk factors analysis of hypersensitivity reactions to abacavir Clin Ther 24 2002 565 573 International AIDS Society Conference on HIV Pathogenesis and treatment 2001, Jul. 8-11:Buenos Aires: abstract 527
3. Clay P.G. The abacavir hypersensitivity reaction: a review Clin Ther 24 2002 1502 1514
4. Hetherington S., McGuirk S., Powell G., Cutrell A., Naderer O., and Spreen B. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir Clin Ther 23 2001 1603 1614
5. Heller H.M. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infections Clin Dermatol 18 2000 485 489
6. Pirmohamed M., and Park B.K. HIV and drug allergy Curr Opin Allergy Clin Immunol 1 2001 311 316
7. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reactions to drugs N Engl J Med 331 1994 1272 1285
8. Smith K.J., Skelton H.G., Yeager J., Ledsky R., Ng T.H., and Wagner K.F. Increased drug reactions in HIV-1 patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research Clin Exp Dermatol 22 1997 118 123
9. Carr A., and Garsia R. Managing HIV. Part 3: mechanisms of disease. 3.5. How HIV leads to hypersensitivity reactions Med J Aust 19 1996 227 229
10. Kalinkovich A., Weisman Z., and Bentwich Z. Chemokines and chemokine receptors: role in HIV infection Immunol Lett 68 1999 281 287
11. Carr A., and Cooper D.A. Adverse effects of antivital therapy Lancet 356 2000 1423 1430
12. Easterbrook P.J., Waters A., Murad S., Taylor C., King D., and Vyakarnam A. Epidemiological risk factors for hypersensitivity reactions to abacavir HIV Med 4 2003 321 324
13. Symonds W., Cutrell A., Edwards M., Steel H., Spreen B., and Powell G. Risk factor analysis of hypersensitivity to abacavir Clin Ther 24 2002 565 573
14. Cutrell A., Hernandez J., Edwards M., Fleming J., Powell W., and Scott T. Clincal risk factors for hypersensitivity reactions to abacavir:: retrospective analysis of over 8,000:subjects receiving abacavir in 34:clinical trials [poster H-2013] 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy 2003 September 14 17 Chicago
15. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., and Moore C. Association between presence of HLA-B5701, HLA- DR7, HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 2002 727 732
16. Hetherington S., Hughes A., Mosteller M., Shortino D., Baker K., and Spreen W. Genetics variations in HLA-B region and hypersensitivity to abacavir Lancet 359 2002 1121 1122
17. Vyakarnam A., King D., and Boaz M. Abacavir induced hypersensitivity in HIV infected individuals is associated with an increased frequency of Th0 T cells Aids 14 2000 S65
18. Ĺoty-Bernard M., Peyrìre H., Hansel S., and Reynes J. Risk factors of hypersensitvity reactions to abacavir [Abstract 77] Antiviral Therapy 6 2001 62 International Workshop on Adverse Drug Reactions and lipodystrophy in HIV, 2001 october 23-26, Athens
19. Hetherington S., Steel H.M., and Lafon S. Safety and tolerance of abacavir (1952, ABC) alone and in combination therapy of HIV infection [abstract 12353] program and abstract of the 12th International Conference on AIDS (Geneva) 1998 International AIDS Society Stocholm 84
20. Witt F., Wood R., Horban A., Beniowski M., Schmidt R.E., and Gray G. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir wih or without nevirapine Aids 15 2001 2423 2429
21. Fauci S., and Bartlett J. The Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretrovial agents in HIV-1 infected adults and adolescents http://www.AIDSinfo.nih.gov 2004 Available from